# US 2021/0071222 A1 · Methods and means for the production of ig-like molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0071222 A1
- Document ID: US20210071222A1
- Status: Published application
- Kind: A1
- Application number: 16/934,925
- Filed: 2020-07-21
- Published: 2021-03-11
- Earliest claimed: 2012-04-20
- Assignees: Merus N.V.
- Applicants: Merus N.V.
- Inventors: Cornelis Adriaan DE KRUIF; Linda Johanna Aleida HENDRIKS; Ton LOGTENBERG
- Web page: https://patentgrep.com/patent/US20210071222A1

## CPC

- A61P 35/00: Antineoplastic agents
- C12P 21/005: {Glycopeptides, glycoproteins}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/40: bacterial
- A61P 37/02: Immunomodulators
- C07K 16/12: against material from bacteria
- C07K 16/1278: Bacillus (G)
- C07K 16/1282: Clostridium (G)
- C07K 16/18: against material from animals or humans
- C07K 16/26: against hormones {; against hormone releasing or inhibiting factors}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/36: against blood coagulation factors
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/31: multispecific
- C07K 2317/526: CH3 domain
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.

## Claims

### Claim 1

A heterodimeric Ig-like molecule comprising two CH3 domains, wherein one of said two CH3 domains comprises at least one substitution of a neutral amino acid residue by a positively charged amino acid residue and wherein the other of said two CH3 domains comprises at least one substitution of a neutral amino acid residue by a negatively charged amino acid residue, wherein the at least one positively charged amino acid residue substituted in the first CH3 domain interacts with the at least one negatively charged amino acid residue substituted in the second CH3 domain.

### Claim 2 (depends on 1)

A heterodimeric Ig-like molecule according to claim 1, wherein one of said two CH3 domains comprises a substitution of the amino acid residue at position 366 by a positively charged amino acid residue, and wherein the other of said two CH3 domains comprises a substitution of the amino acid residue at position 351 by a negatively charged amino acid residue.

### Claim 3 (depends on 1)

A heterodimeric Ig-like molecule according to claim 1, wherein a first CH3 domain comprises a substitution of the amino acid residue at position 366 by a lysine (K) residue, and wherein a second CH3 domain comprises a substitution of the amino acid residue at position 351 by an aspartic acid (D) residue.

### Claim 4 (depends on 3)

A heterodimeric Ig-like molecule according to claim 3, wherein the 1st CH3 domain further comprises a substitution of the amino acid residue at position 351 by a lysine (K) residue.

### Claim 5 (depends on 3)

A heterodimeric Ig-like molecule according to claim 3, wherein the 2nd CH3 domain further comprises amino acid substitution(s) selected from the group consisting of
(i) a substitution of the amino acid residue at position 349 by a glutamic acid (E) residue;
(ii) a substitution of the amino acid residue at position 349 by an aspartic acid (D) residue;
(iii) a substitution of the amino acid residue at position 368 by a glutamic acid (E) residue;
(iv) a substitution of the amino acid residue at position 349 by an aspartic acid (D) residue, and a substitution of the amino acid residue at position 368 by a glutamic acid (E) residue; and
(v) substitution of the amino acid residues at positions 349 and 355 by aspartic acid (D) residues.

### Claim 6 (depends on 5)

A heterodimeric Ig-like molecule according to claim 5, wherein the 2nd CH3 domain comprises the substitution of the amino acid residue at position 368 by a glutamic acid (E) residue.

### Claim 7 (depends on 1)

A heterodimeric Ig-like molecule according to claim 1, wherein a first CH3 domain comprises an amino acid substitution at position 351 by a negatively charged amino acid residue and an amino acid substitution at position 368 by a negatively charged amino acid residue, and wherein a second CH3 domain comprises an amino acid substitution at position 366 by a positively charged amino acid residue and an amino acid substitution at position 351 by a positively charged amino acid residue.

### Claim 8 (depends on 7)

A heterodimeric Ig-like molecule according to claim 7, wherein the first CH3 domain comprises an amino acid substitution at position 351 by an aspartic acid (D) and an amino acid substitution at position 368 by a glutamic acid (E), and wherein the second CH3 domain comprises an amino acid substitution at position 366 by a lysine (K) and an amino acid substitution at position 351 by a lysine (K).

### Claim 9 (depends on 1)

A heterodimeric Ig-like molecule according to claim 1, that further comprises a common light chain.

### Claim at position 10

10-12. (canceled)

### Claim 13 (depends on 1)

A heterodimeric Ig-like molecule according to claim 1, wherein the Ig-like molecule is an antibody.

### Claim 14 (depends on 1)

A heterodimeric Ig-like molecule according to claim 1, wherein the Ig-like molecule is human IgG.

### Claim 15 (depends on 1)

A heterodimeric Ig-like molecule according to claim 1, wherein said heterodimeric Ig-like molecule binds to different epitopes on the same antigen or to different epitopes on different antigens.

### Claim at position 14

16-17. (canceled)

### Claim 18 (depends on 16)

A heterodimeric Ig-like molecule according to claim 16, wherein the target molecule is a membrane-bound molecule.

### Claim 19 (depends on 15)

A heterodimeric Ig-like molecule according to claim 15, wherein the different target epitopes are located on different target molecules.

### Claim 20

(canceled)

### Claim 21 (depends on 19)

A heterodimeric Ig-like molecule according to claim 19, wherein the different target molecules are expressed on different cells.

### Claim 22

(canceled)

### Claim 23 (depends on 19)

A heterodimeric Ig-like molecule according to claim 19, wherein one target molecule is a soluble molecule whereas the second target molecule is a membrane bound molecule.

### Claim 24 (depends on 15)

A heterodimeric Ig-like molecule according to claim 15, wherein at least one of said epitopes is located on a tumor cell.

### Claim 25 (depends on 15)

A heterodimeric Ig-like molecule according to claim 15, wherein at least one of said epitopes is located on an effector cell.

### Claim 26 (depends on 25)

A heterodimeric Ig-like molecule according to claim 25, wherein said effector cell is an NK cell, a T cell, a B cell, a monocyte, a macrophage, a dendritic cell or a neutrophilic granulocyte.

### Claim 27 (depends on 15)

A heterodimeric Ig-like molecule according to claim 15, wherein said epitope is located on a CD3, CD16, CD25, CD28, CD64, CD89, NKG2D or a NKp46 molecule.

### Claim 28 (depends on 1)

A pharmaceutical composition comprising a heterodimeric Ig-like molecule according to claim 1 and a pharmaceutically acceptable carrier.
